AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03703700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zishen Yutai Pill
Description: Patients who undergo the long-term protocol will start taking Zishen Yutai Pill on the day of pituitary suppression, 5g three times a day (Stopping on the first 1-4 days of menstruation), and patients who undergo the antagonist protocol will start taking Zishen Yutai Pill on the 19th to 23rd day of the previous menstruation cycle, 5g three times a day (Stopping on the first 1-4 days of menstruation). The drug will be taken till 2 weeks after transplantation. If the test result is confirmed as biochemical pregnancy (HCG>50 IU/L), patients continue to take pills till 3 weeks after the clinical pregnancy determined by the ultrasound. If it is determined that the pregnancy test is negative, stop the drug.
Study NCT03703700 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients who undergo the long-term protocol will start taking Placebo on the day of pituitary suppression, 5g three times a day (Stopping on the first 1-4 days of menstruation), and patients who undergo the antagonist protocol will start taking Placebo on the 19th to 23rd day of the previous menstruation cycle, 5g three times a day (Stopping on the first 1-4 days of menstruation). The drug will be taken till 2 weeks after transplantation. If the test result is confirmed as biochemical pregnancy (HCG>50 IU/L), patients continue to take pills till 3 weeks after the clinical pregnancy determined by the ultrasound. If it is determined that the pregnancy test is negative, stop the drug.
Study NCT03228446 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: filter training
Description: one-week filter training on the computer: computerized visual change detection experiment (selective attention )
Study NCT03228446 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: memory training
Description: one-week storage training on the computer: computerized visual change detection experiment (memory storage)
Study NCT03228446 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no training (control)
Description: no training applied
Study NCT00702481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Patients will receive nimotuzumab 200 mg weekly for 8 weeks. Nimotuzumab will be started together with concurrent chemoradiation, and continued 1 week after the completion of chemoradiation.
Study NCT00702481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Concurrent chemotherapy with cisplatin 100 mg/m2 will be given on week 1, 4, and 7 of radiotherapy.
Study NCT00702481 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Concurrent radiotherapy will be given to the primary tumor and upper neck at 2 Gy per fraction, once a day, five days a week to a total of 70 Gy in 35 fractions in seven weeks.
Study NCT02860494 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months, by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
Study NCT00995969 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1.0 g (w/w) placebo cream applied to both target lesions twice daily
Study NCT00995969 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CT 327
Description: 1.0 g CT 327 cream will be applied to one target lesion twice daily and 1.0 g placebo cream will be applied to the remaining target lesion twice daily
Study NCT02927301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
Description: Atezolizumab was given as 1200 milligrams (mg) via intravenous (IV) infusion on Day 1 of each 21-day cycle.
Study NCT04961710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag Olamine
Description: Hetrombopag Olamine; once daily
Study NCT04961710 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo; once daily
Study NCT01351909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given PO
Study NCT01351909 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01351909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study NCT03317860 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand. tDCS is a form of noninvasive brain stimulation. Electrodes will be placed on the scalp but in the sham condition they will not deliver direct current (2mA). Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand.~Repetitive task-specific practice (RTP). Participants will practice using their paretic arm/hand to complete functional movements during the 30 minute train
Study NCT03317860 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS
Description: Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand. tDCS is a form of noninvasive brain stimulation. Electrodes will be placed on the scalp but in the sham condition they will not deliver direct current (2mA). Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand.~Repetitive task-specific practice (RTP). Participants will practice using their paretic arm/hand to complete functional movements during the 30 minute train
Study NCT03604367 — intervention group
Intervention type: DEVICE
Intervention: GAITRite assessment
Description: The fMRI Bipedal Paradigm will allow investigators to study the effects treadmill-assisted gait training have on cortical control of bipedal movement in chronic stroke patients.
Study NCT00115570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Description: Subcutaneous injection
Study NCT00115570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin lispro
Description: Subcutaneous injection
Study NCT00115570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: Subcutaneous injection once daily
Study NCT00115570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Subcutaneous injection once daily
Study NCT00115570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPH insulin
Description: subcutaneous injection twice daily
Study NCT00115570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH insulin
Description: subcutaneous injection twice daily
Study NCT00287105 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standard chemotherapy + Imatinib
Description: Patients receive Imatinib together with the standard chemotherapy regimen of phase IB and after each of three consecutive blocks of the standard chemotherapy in the consolidation phase
Study NCT02720393 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No-carrageenan diet
Description: Diet of food items that have no carrageenan as selected by study dietician.
Study NCT02720393 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Regular Diet
Description: Diet of food items that have carrageenan as selected by study dietician
Study NCT00442169 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChimeriVax-WN02 Low Dose
Description: Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region.
Study NCT00442169 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChimeriVax-WN02 Medium Dose
Description: Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
Study NCT00442169 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChimeriVax-WN02 High Dose
Description: Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
Study NCT00442169 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline solution
Description: Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
Study NCT00442169 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0.9 % NaCl solution
Description: Single dose given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
Study NCT01921205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Subjects \<30 kg (LCM oral solution): 4 mg/kg - 6 mg/kg BID ( 8mg/kg/day - 12 mg/kg/day)~Subjects ≥30 kg to \<50 kg (LCM oral solution): 3 mg/kg - 4 mg/kg BID (6 mg/kg/day - 8 mg/kg/day)~Subjects ≥50 kg (LCM tablets): 150 mg - 200 mg BID (300 mg/day - 400 mg/day)
Study NCT01921205 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects \<30 kg (placebo oral solution): 4 mg/kg - 6 mg/kg BID (8 mg/kg/day - 12 mg/kg/day)~Subjects ≥30 kg to \<50 kg (placebo oral solution): 3 mg/kg - 4 mg/kg BID (6 mg/kg/day - 8 mg/kg/day)~Subjects ≥50 kg (placebo tablets): 150 mg - 200 mg BID (300 mg/day - 400 mg/day)
Study NCT04356222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Intravenous infusion once every two weeks ,once 10mg/kg.
Study NCT04356222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Intrathecal chemotherapy specified dose on specified days
Study NCT01149850 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT01149850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given orally
Study NCT01149850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01149850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies
Study NCT01149850 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: microarray analysis
Description: Correlative studies
Study NCT01149850 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA methylation analysis
Description: Correlative studies
Study NCT03596216 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PENS
Description: This intervention consisted in the application of an asymmetric biphasic rectangular current of 150 microseconds and 10 Hz using a specifically developed medically certified device (Physio Invasive, Enraf Nonius, Prim, SPAIN). This is an invasive intervention by ultrasound and needles.
Study NCT03596216 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TENS
Description: This intervention consisted in the application of an asymmetric biphasic rectangular current of 150 microseconds and 10 Hz using a specifically developed medically certified device (Physio Invasive, Enraf Nonius, Prim, SPAIN). This is a non-invasive intervention by self-adhesive electrodes.
Study NCT02456012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral esomeprazole 20 mg twice daily
Description: for 36 weeks
Study NCT02456012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral esomeprazole 20 mg once daily
Description: for 36 weeks
Study NCT03908034 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: presence of uncontrollable risk factor
Description: the presence of an uncontrollable / unremovable risk factor for a disease
Study NCT03908034 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: induction of anticipated regret
Description: higher level of elaboration on potential regret
Study NCT00758732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel at the dose of 75mg/m2 over a 60 min intravenous infusion every 3 weeks for a maximum of 6 consecutive cycles
Study NCT00758732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin 5 AUC over a 90 min intravenous infusion every 3 weeks for a maximum of 6 consecutive cycles
Study NCT00758732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel at the dose of 40mg/m2 over a 60 min intravenous infusion every 2 weeks in 28 days cycle for a maximum of 6 consecutive cycles.
Study NCT00758732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal doxorubicin
Description: Liposomal doxorubicin at the dose of 20 mg/m2 over a 90 min intravenous infusion every 2 weeks in 28 days cycle for a maximum of 6 consecutive cycles.
Study NCT00987376 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diagnostic Imaging: C11 choline PET; C11 acetate PET; and MRI Spectroscopy
Description: C11 Choline, C11 Acetate PET and MRI
Study NCT01457651 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar recruitment
Description: Four approaches:~1. CPAP 40 cm H2O~2. Peak pressure 40 cm H2O~3. PEEP 15 cm H2O for 300 sec~4. no intervention (controls)
Study NCT05475249 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implant placement and prothesis made with different types of abutment
Description: Dental implants (Tapered internal implants; BioHorizons, Birmingham, EEUU) will be placed in healed residual ridges (minimum of 4 months after tooth extraction). After connecting healing abutments, the flaps will be sutured around the abutments for non-submerged healing. An abutment composed of white yttrium oxide stabilized zirconia abutment (PYRCA; BioHorizons, Birmingham, EEUU) previously immersed in fluorescent liquid (Zirkonzahn, South Tirol, Italy) will be placed in the test group, whether in the control group the same abutment will be used but without fluorescent layer. The selected abutment is machined and designed for use with cemented restorations. A single experienced restorative dentist using one dental laboratory carried out all the prosthetic procedures. Single crowns full ceramic will be performed and cemented with RelyX™ Luting Cement.
Study NCT05475249 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Implant placement and prothesis made with different types of abutment
Description: Dental implants (Tapered internal implants; BioHorizons, Birmingham, EEUU) will be placed in healed residual ridges (minimum of 4 months after tooth extraction). After connecting healing abutments, the flaps will be sutured around the abutments for non-submerged healing. An abutment composed of white yttrium oxide stabilized zirconia abutment (PYRCA; BioHorizons, Birmingham, EEUU) previously immersed in fluorescent liquid (Zirkonzahn, South Tirol, Italy) will be placed in the test group, whether in the control group the same abutment will be used but without fluorescent layer. The selected abutment is machined and designed for use with cemented restorations. A single experienced restorative dentist using one dental laboratory carried out all the prosthetic procedures. Single crowns full ceramic will be performed and cemented with RelyX™ Luting Cement.
Study NCT01089504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phenobarbital
Description: Phenobarbital, 4-5 mg/kg/d, by mouth, for 4 months
Study NCT01089504 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matched placebo, same volume as active drug, by mouth daily for 4 months
Study NCT02740946 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Description: 5 months of exercise therapy with two strengthening exercises focusing on m. deltoideus anterior and m. teres minor. Furthermore, a warm up exercise was applied.
Study NCT01924845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 701
Description: BMN 701 20 mg/kg for intravenous administration over approximately 4 hours every 2 weeks over a 24-week Treatment Period (total of 13 doses), and every 2 weeks over a 240-week Extension Period (up to 120 additional doses).
Study NCT02739230 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exparel
Study NCT02739230 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: On-Q pain intra-articular catheter
Study NCT02485782 — intervention group
Intervention type: DEVICE
Intervention: CardioScreen 1000 - Haemodynamic Measurement System, Medis
Description: Impedance cardiography (ICG)
Study NCT02485782 — intervention group
Intervention type: DEVICE
Intervention: BCM- Body Composition Monitor, Fresenius Medical Care
Description: Information about the individual fluid status and the nutritional status.
Study NCT03969485 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid Fractional Laser
Description: Hybrid Fractional Laser Device
Study NCT02485782 — intervention group
Intervention type: DEVICE
Intervention: SCHILLER, BR-102 plus, Ambulatory Blood Pressure Monitoring System
Description: Blood pressure monitoring every 15 min during hemodialysis
Study NCT04661956 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transbronchial cryobiopsy/Transbronchial lung biopsy (forcep)
Description: Transbronchial lung biopsy by cryoprobe or by forcep
Study NCT04661956 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transbronchial cryobiopsy/Transbronchial lung biopsy (forcep)
Description: Transbronchial lung biopsy by cryoprobe or by forcep
Study NCT01825928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone
Description: Paliperidone group,3mg/pill,3mg/day forced titration method,last 84 days
Study NCT01825928 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo group,3mg/pill,3mg/day forced titration method,last 84 days
Study NCT03596034 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL 5%, Virginia Tobacco, ENDS product
Description: Subjects participate in a 15 day product use period during which subjects will be requested to predominantly use the JUUL 5% product ad libitum as their primary source of nicotine. Subjects will be asked to report their daily use of the JUUL 5% product and CPD throughout the 15 day product use period.
Study NCT04268459 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Provox prosthesis exchange
Description: Each patient post laryngectomy will be randomly assigned to one arm of intervention. The voice prosthesis exchange in all patients will be performed in local anaesthesia. The microbiological samples with cotton swabs will be collected from tracheoesophageal fistula on prosthesis exchange. The clinical evaluation and patients satisfaction from prosthesis usage will be performed on each exchange.
Study NCT02868112 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Oncology Care
Description: Participants receiving usual oncology care will not meet routinely with geriatric clinicians, though they may receive a geriatrics consult at their request or at the discretion of their treating team.
Study NCT02868112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transdisciplinary Intervention
Description: Patients randomized to the transdisciplinary intervention will undergo evaluation with a board-certified geriatric clinician, who will tailor their care based on the results of a brief geriatric screening tool, completed prior to their visit. We will test a two-visit transdisciplinary intervention with the first visit occurring within four weeks of enrollment and the second visit four weeks after the initial visit.
Study NCT02190526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalazine(asacol 800 mg)
Study NCT02190526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Study NCT02190526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo like asacol
Study NCT02190526 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo like asacol
Study NCT02190526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo like amitriptyline
Study NCT02190526 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo like amitriptyline
Study NCT03851458 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Initial in-person individual diet and exercise counseling (N vs. Y)
Description: Individual counseling utilizing MI has been effective in promoting behavioral change.18 A SANOS interventionist (MRNY promotora) will deliver a 45-60 minute counseling session, utilizing MI techniques, on diet and exercise, and how to stretch one's food dollars (see description of 10 modules described above under COMIDA Pilot). The promotora will evaluate the participant's diet based on the 24-hour dietary recall132 conducted at intake (see below), will compare diet composition to the USDA's MyPlate guidelines, and will then personalize education to address identiﬁed knowledge gaps and unhealthy food choices. Promotoras will focus on goal-setting, problem solving, selfeﬃcacy enhancements, selfmonitoring skills (i.e., participants will be taught how to monitor their diet, weight, and physical activity (PA), with simple pencil-and-paper logs or with 'Self-monitoring tools' if randomized to also receive that component), and modeling of healthy behaviors.